Soligenix Inc. (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March 2. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Miami Beach, Florida, will feature company presentations, one-on-one meetings and programming focused on growth-stage biotechnology companies. Additional information is available on the conference website.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the company's first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behcet’s Disease. The Public Health Solutions business segment includes development programs for RiVax®, the company's ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, a vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
The development of the vaccine programs incorporates the use of the company's proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX.
The CEO's presentation at this prominent investment summit provides a significant platform to highlight Soligenix's diverse pipeline to potential investors and partners. For patients with rare conditions like CTCL, the advancement of HyBryte™ toward potential commercialization represents a promising new treatment option utilizing a novel mechanism. The company's public health vaccine programs, supported by government agencies, address critical biodefense and pandemic preparedness needs. The ThermoVax® platform technology could enable more stable, easily distributed vaccines for threats like ricin, Ebola, and coronaviruses. This corporate update at a major industry event underscores Soligenix's position as a developer of both specialized therapeutics for underserved patient populations and broader public health solutions, with multiple late-stage assets nearing key milestones.
